Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
$4.80M
Mr. Michael S. Poirier
39.00
Carlsbad, CA
Jun 24, 2015
-0.11
$-1.64
0.16
0.57
-328.56%
-0.18
1.72
0.58
0.24
-151.55%
-303.21%
Similar stocks (14)
Assembly Biosciences, Inc.
ASMB
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRB
Anebulo Pharmaceuticals, Inc.
ANEB
Immix Biopharma, Inc.
IMMX
Indaptus Therapeutics, Inc.
INDP
Kiora Pharmaceuticals, Inc.
KPRX
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
Salarius Pharmaceuticals, Inc.
SLRX
180 Life Sciences Corp.
ATNF
TRACON Pharmaceuticals, Inc.
TCON
Navidea Biopharmaceuticals, Inc.
NAVB
Aridis Pharmaceuticals, Inc.
ARDS
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (14)
Assembly Biosciences, Inc.
ASMB
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRB
Anebulo Pharmaceuticals, Inc.
ANEB
Immix Biopharma, Inc.
IMMX
Indaptus Therapeutics, Inc.
INDP
Kiora Pharmaceuticals, Inc.
KPRX
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
Salarius Pharmaceuticals, Inc.
SLRX
180 Life Sciences Corp.
ATNF
TRACON Pharmaceuticals, Inc.
TCON
Navidea Biopharmaceuticals, Inc.
NAVB
Aridis Pharmaceuticals, Inc.
ARDS
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%